Amarantus BioScience (AMBS) 10-Q 23 Nov 15 2015 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2015	Nov. 20, 2015
Document And Entity Information [Abstract]
Entity Registrant Name	Amarantus Bioscience Holdings, Inc.
Entity Central Index Key	1,424,812
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Type	10-Q
Document Period End Date	Sep. 30, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q3
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		13,499,000

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 278	$ 214
Deferred financing fees	162
Prepaid expenses and other current assets	595	$ 402
Total current assets	1,035	616
Property and equipment, net	135	145
Intangible assets, net	14,213	1,497
Total assets	15,383	2,258
Current liabilities:
Accounts payable and accrued liabilities	$ 6,302	3,502
Accounts payable - Regenicin		2,550
Related party liabilities and accrued interest	$ 256	252
Accrued interest	74	$ 25
Notes payable	$ 1,180
Senior secured convertible notes payable, net of discount $6.7 million and $0 as of September 30, 2015 and December 31, 2014, respectively
Derivative liability	$ 8,364
Total current liabilities	16,176	$ 6,329
Total liabilities	$ 16,176	$ 6,329
Commitment and Contingencies
Series H, $1,000 stated value; 10,000 shares designated; 3,056 and 0 issued and outstanding as of September 30, 2015 and December 31, 2014, respectively; aggregate liquidation preference of $5,435	$ 2,413
Stockholders' equity (deficit)
Common stock, $0.001 par value, 35,000,000 authorized; 9,113,000 and 5,615,000 shares issued and outstanding at September 30, 2015 and December 31, 2014, respectively	9	$ 6
Additional paid-in capital	69,557	45,886
Accumulated deficit	(81,671)	(55,183)
Total stockholders' equity (deficit) and temporary equity	(794)	(4,072)
Total liabilities and stockholders' equity (deficit) and temporary equity	$ 15,383	$ 2,258
Series A Preferred Stock [Member]
Stockholders' equity (deficit)
Convertible preferred stock
Series B Preferred Stock [Member]
Stockholders' equity (deficit)
Convertible preferred stock
Series C Preferred Stock [Member]
Stockholders' equity (deficit)
Convertible preferred stock	$ 1	$ 1
Series D Preferred Stock [Member]
Stockholders' equity (deficit)
Convertible preferred stock		1,169
Series E Preferred Stock [Member]
Stockholders' equity (deficit)
Convertible preferred stock	$ 8,898	$ 4,050
Series G Preferred Stock [Member]
Stockholders' equity (deficit)
Convertible preferred stock
Series H Preferred Stock [Member]
Stockholders' equity (deficit)
Convertible preferred stock

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	35,000,000	35,000,000
Common stock, shares issued	113,000	5,615,000
Common stock, shares outstanding	113,000	5,614,605
Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Series A Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock shares, designated	250,000	250,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Series B Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock shares, designated	3,000,000	3,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Series C Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock shares, designated	750,000	750,000
Preferred stock, shares issued	750,000	750,000
Preferred stock, shares outstanding	750,000	750,000
Series D Preferred Stock [Member]
Preferred stock, par value	$ 1,000	$ 1,000
Preferred stock shares, designated	1,300	1,300
Preferred stock, shares issued	0	1,299
Preferred stock, shares outstanding	0	1,299
Preferred stock, liquidation preference, value	$ 350	$ 350
Series E Preferred Stock [Member]
Preferred stock, par value	$ 1,000	$ 1,000
Preferred stock shares, designated	13,335	13,335
Preferred stock, shares issued	9,888	4,500
Preferred stock, shares outstanding	9,888	4,500
Preferred stock, liquidation preference, value	$ 12,670	$ 7,722
Series G Preferred Stock [Member]
Preferred stock, par value	$ 5,000	$ 5,000
Preferred stock shares, designated	10,000	10,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Income Statement [Abstract]
Net sales
Operating expense:
Research and development	$ 1,513	$ 1,899	$ 6,247	$ 4,056
General and administrative	2,043	2,070	9,439	5,289
Total operating expense	3,556	3,969	15,686	9,345
Loss from operations	(3,556)	(3,969)	(15,686)	(9,345)
Other income (expense):
Interest expense	$ (245)	(46)	$ (415)	(756)
Loss on issuance of common stock		$ (193)		(260)
Loss on issuance of senior secured convertible promissory notes	$ (1,645)		$ (1,645)	(3,868)
Other Income (expense)		$ (74)		(92)
Change in fair value of warrant & derivative liabilities		(117)		356
Total other income (expense)	$ (1,890)	(430)	$ (2,060)	(4,620)
Net loss	(5,722)	(4,399)	(12,302)	(13,965)
Preferred stock dividend	3,187	26	4,016	78
Net loss attributable to common stockholders	$ (8,909)	$ (4,425)	$ (16,318)	$ (14,043)
Basic and diluted net loss per common share	$ (0.98)	$ (0.86)	$ (3.37)	$ (2.96)
Basic and diluted weighted average common shares outstanding	8,000,000	5,118,000	7,157,031	4,744,000

Condensed Consolidated Stateme5

Condensed Consolidated Statements Statement of Stockholders' Equity (Deficit) and Temporary Equity (Unaudited) - USD ($)	Total	Convertible Preferred Stock	Common Stock	Additional Paid-in Capital	Accumulated Deficit
Beginning Balance at Dec. 31, 2014	$ (4,072,000)	$ 5,220,000	$ 6,000	$ 45,887,000	$ (55,185,000)
Beginning Balance, Shares at Dec. 31, 2014		755,799	5,614,605
Common Stock issued for cash
Common Stock issued for cash, Shares
Common stock issued for funding fees	$ 2,820,000			$ 2,820,000
Common stock issued for funding fees, Shares			259,595
Common stock issued for funding fees - to LPC as req'd at drawdown
Common stock issued for acquisition of Diogneix	$ 7,951,000		$ 1,000	$ 7,950,000
Common stock issued for acquisition of Diogneix, Shares			662,526
Series E BCF Adj for Price reset from $7.50 to $4.50
Series E BCF 12% Notes
Common Stock issued for Series D convertible preferred stock quarterly dividend	$ 35,000			$ 35,000
Common Stock issued for Series D convertible preferred stock quarterly dividend, Shares			7,820
Common Stock issued for Series E convertible preferred stock quarterly dividend	237,000			$ 237,000
Common Stock issued for Series E convertible preferred stock quarterly dividend, Shares			21,738
Sale of Series E preferred stock	$ 2,950,000	$ 2,950,000
Sale of Series E preferred stock, Shares		3,278
Sale of Series G preferred stock
Sale of Series G preferred stock, Shares
Sale of Series H preferred stock
Sale of Series H preferred stock, Shares
Series E convertible preferred stock accretion of beneficial conversion feature as deemed dividend				$ 441,000	$ (441,000)
Repurchase of Series G
Repurchase of Series G, Shares
Legal fees related to stock financing	$ (19,000)			$ (19,000)
SEC filing fee
Common Stock issued in conversion of Series D pref stock		$ (494,000)		$ 494,000
Common Stock issued in conversion of Series D pref stock, Shares		(549)	122,073
Common Stock issued in conversion of Series E pref stock		$ (450,000)		$ 450,000
Common Stock issued in conversion of Series E pref stock, Shares		(500)	41,667
Common Stock issued in conversion of Series G pref stock
Common Stock issued in conversion of Series G pref stock, Shares
Common stock issued to Series E holders
Common stock issued to Series E holders, Shares
Common stock issued for Series D convertible preferred stock dividend upon conversion					$ (9,000)
Common stock issued for Series E convertible preferred stock dividend upon conversion					$ (172,000)
Common stock issued for Series E convertible preferred stock dividend upon conversion, Shares
Common stock issued for Series G convertible preferred stock dividend upon conversion
Common stock issued for Series G convertible preferred stock dividend upon conversion, Shares
Common stock issued as fee for debt financing arrangement	$ 103,000			$ 103,000
Common stock issued as fee for debt financing arrangement, Shares			8,333
Series D dividend accrued	(24,000)				$ (24,000)
Series E dividend accrued	(364,000)				$ (364,000)
Series G dividend accrued
Common stock issued for service	$ 106,000			$ 106,000
Common stock issued for service, Shares			9,028
Series G Write off
Cancelled Shares of Series G
Cancelled Shares of Series G, Shares
Stock-based compensation expense	$ 488			$ 488
Net loss	(6,580,000)				$ (6,580,000)
Ending Balance at Mar. 31, 2015	3,631,000	$ 7,226,000	$ 7,000	$ 58,992,000	(62,594,000)
Ending Balance, Shares at Mar. 31, 2015		758,028	6,747,385
Beginning Balance at Dec. 31, 2014	(4,072,000)	$ 5,220,000	$ 6,000	45,887,000	(55,185,000)
Beginning Balance, Shares at Dec. 31, 2014		755,799	5,614,605
Net loss	(12,302,000)
Ending Balance at Sep. 30, 2015	(794,000)	$ 9,765,000	$ 8,000	71,505,000	(82,072,000)
Ending Balance, Shares at Sep. 30, 2015		762,944	9,112,663
Beginning Balance at Mar. 31, 2015	$ 3,631,000	$ 7,226,000	$ 7,000	$ 58,992,000	$ (62,594,000)
Beginning Balance, Shares at Mar. 31, 2015		758,028	6,747,385
Common Stock issued for cash
Common Stock issued for cash, Shares
Common stock issued for funding fees
Common stock issued for funding fees, Shares
Common stock issued for funding fees - to LPC as req'd at drawdown
Common stock issued for funding fees - to LPC as req'd at drawdown, Shares
Common stock issued for acquisition of Diogneix
Common stock issued for acquisition of Diogneix, Shares
Series E BCF Adj for Price reset from $7.50 to $4.50				$ 2,835,000	$ (2,835,000)
Series E BCF 12% Notes
Common Stock issued for Series D convertible preferred stock quarterly dividend	$ 16,000			$ 16,000
Common Stock issued for Series D convertible preferred stock quarterly dividend, Shares			3,620
Common Stock issued for Series E convertible preferred stock quarterly dividend	192,000			$ 192,000
Common Stock issued for Series E convertible preferred stock quarterly dividend, Shares			25,850
Sale of Series E preferred stock	400,000	$ 400,000
Sale of Series E preferred stock, Shares		444
Sale of Series G preferred stock	$ 4,950,000	$ 4,950,000
Sale of Series G preferred stock, Shares		1,087
Sale of Series H preferred stock
Sale of Series H preferred stock, Shares
Series E convertible preferred stock accretion of beneficial conversion feature as deemed dividend
Repurchase of Series G
Repurchase of Series G, Shares
Legal fees related to stock financing	$ (134,000)			$ (134,000)
SEC filing fee
Common Stock issued in conversion of Series D pref stock		$ (360,000)		$ 360,000
Common Stock issued in conversion of Series D pref stock, Shares		(400)	88,888
Common Stock issued in conversion of Series E pref stock
Common Stock issued in conversion of Series E pref stock, Shares
Common Stock issued in conversion of Series G pref stock
Common Stock issued in conversion of Series G pref stock, Shares
Common stock issued to Series E holders
Common stock issued to Series E holders, Shares			200,000
Common stock issued for Series D convertible preferred stock dividend upon conversion
Common stock issued for Series D convertible preferred stock dividend upon conversion, Shares
Common stock issued for Series E convertible preferred stock dividend upon conversion
Common stock issued for Series E convertible preferred stock dividend upon conversion, Shares
Common stock issued for Series G convertible preferred stock dividend upon conversion
Common stock issued for Series G convertible preferred stock dividend upon conversion, Shares
Common stock issued as fee for debt financing arrangement	$ 14,000			$ 14,000
Common stock issued as fee for debt financing arrangement, Shares			1,867
Series D dividend accrued	(8,000)				$ (8,000)
Series E dividend accrued	(231,000)				(231,000)
Series G dividend accrued	(114,000)				$ (114,000)
Common stock issued for service	$ 98,000			$ 98,000
Common stock issued for service, Shares			17,360
Series G Write off
Cancelled Shares of Series G
Cancelled Shares of Series G, Shares
Stock-based compensation expense	$ 318			$ 318
Net loss	(5,721,000)				$ (5,721,000)
Ending Balance at Jun. 30, 2015	3,411,000	$ 12,216,000	$ 7,000	$ 62,691,000	$ (71,503,000)
Ending Balance, Shares at Jun. 30, 2015		759,159	7,084,970
Common Stock issued for cash	$ 63,000			$ 63,000
Common Stock issued for cash, Shares			13,334
Common stock issued for funding fees
Common stock issued for funding fees, Shares
Common stock issued for funding fees - to LPC as req'd at drawdown
Common stock issued for funding fees - to LPC as req'd at drawdown, Shares			74
Common stock issued for acquisition of Diogneix
Common stock issued for acquisition of Diogneix, Shares
Series E BCF Adj for Price reset from $7.50 to $4.50
Series E BCF 12% Notes
Series H BCF Adj				$ (1,202,000)	$ 1,202,000
Common Stock issued for Series D convertible preferred stock quarterly dividend	$ 50,000			50,000
Common Stock issued for Series D convertible preferred stock quarterly dividend, Shares			18,909
Common Stock issued for Series E convertible preferred stock quarterly dividend	8,000			8,000
Common Stock issued for Series E convertible preferred stock quarterly dividend, Shares			416,173
Sale of Series E preferred stock	230,000	$ 1,949,000		$ 230,000	$ (50,000)
Sale of Series E preferred stock, Shares		2,166	416,173
Sale of Series G preferred stock	$ 2,000,000	$ 2,000,000
Sale of Series G preferred stock, Shares		535
Sale of Series H preferred stock		$ 2,143,000
Sale of Series H preferred stock, Shares		3,056
Series E convertible preferred stock accretion of beneficial conversion feature as deemed dividend
Repurchase of Series G	$ (5,140,000)	$ (5,140,000)
Repurchase of Series G, Shares		(1,260)
Legal fees related to stock financing
SEC filing fee	$ (135,000)			$ (135,000)
Common Stock issued in conversion of Series D pref stock
Common Stock issued in conversion of Series D pref stock, Shares
Common Stock issued in conversion of Series E pref stock	$ 315,000		$ 77,778	$ 315,000
Common Stock issued in conversion of Series E pref stock, Shares
Common Stock issued in conversion of Series G pref stock					$ (440,000)
Common Stock issued in conversion of Series G pref stock, Shares
Common stock issued to Series E holders		$ (1,810,000)		$ 1,810,000
Common stock issued to Series E holders, Shares		(362)	201,112
Common stock issued for Series D convertible preferred stock dividend upon conversion	$ (315,000)	$ (350,000)
Common stock issued for Series D convertible preferred stock dividend upon conversion, Shares		(315)
Common stock issued for Series E convertible preferred stock dividend upon conversion
Common stock issued for Series E convertible preferred stock dividend upon conversion, Shares
Common stock issued for Series G convertible preferred stock dividend upon conversion	$ 2,087,000		$ 1,000	$ 2,086,000
Common stock issued for Series G convertible preferred stock dividend upon conversion, Shares			1,452,400
Common stock issued as fee for debt financing arrangement
Common stock issued as fee for debt financing arrangement, Shares
Series D dividend accrued	$ 31,000			$ 32,000	$ (1,000)
Series D dividend accrued, Shares			15,000
Series E dividend accrued	(289,000)				(289,000)
Series G dividend accrued	(1,974,000)				$ (1,974,000)
Common stock issued for service	152,000			$ 152,000
Common stock issued for service, Shares			45,000
Series G Write off	$ 390,000			$ 390,000
Cancelled Shares of Series G
Cancelled Shares of Series G, Shares			(212,087)
Nervada Warrant Liability	$ (948,000)	$ (1,548,000)		$ 600,000
Stock-based compensation expense	401,000			$ 401,000
Net loss	(5,722,000)				$ (5,442,000)
Ending Balance at Sep. 30, 2015	$ (794,000)	$ 9,765,000	$ 8,000	$ 71,505,000	$ (82,072,000)
Ending Balance, Shares at Sep. 30, 2015		762,944	9,112,663

Condensed Consolidated Stateme6

Condensed Consolidated Statements Statement of Stockholders' Equity (Deficit) and Temporary Equity (Unaudited) (Parenthetical) - $ / shares	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015
Percentage of notes	12.00%
Series E BCF [Member]
Percentage of notes	12.00%	12.00%	12.00%
Minimum [Member]
Share Price	$ 4.50	$ 4.50	$ 4.50
Maximum [Member]
Share Price	$ 7.50	$ 7.50	$ 7.50

Condensed Consolidated Stateme7

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Cash flows from operating activities
Net loss	$ (12,302)	$ (13,965)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization	$ 60	17
Amortization of debt discount		582
Amortization of deferred financing fees	$ 104	145
Amortization of intangible assets	96	86
Stock issued for services	$ 388	648
Write-off of clinical material		500
Reserve for investment		25
Loss on stock issuance		260
Loss on warrant issuance	$ 1,645	3,868
Non-cash interest expense related to demand promissory note, warrants and derivative		37
Change in fair value of warrants and derivative liability		(356)
Stock-based compensation expense	$ 1,208	914
Changes in assets and liabilities:
Restricted Cash		(129)
Clinical trial material		(500)
Deferred funding fees	$ (150)	116
Prepaid expenses and other current assets	$ (50)	(180)
Accounts Payable and accrued expenses		947
Related party liabilities and accrued interest	$ 3	$ 3
Accrued interest	$ 258
Accounts expenses and accrued interest		$ 57
Net cash used in operating activities	$ (14,075)	$ (6,926)
Cash flows from investing activities
Acquisition of DioGenix, Inc.	$ (1,098)
Investment		$ (25)
Acquisition of Cutanogen, Inc.	$ (4,000)
Acquisition of property and equipment	$ (11)	(144)
Acquisition other assets		(600)
Net cash used in investing activities	$ (5,109)	(769)
Cash flows from financing activities
Proceeds from notes payable	4,680	$ 500
Proceeds from senior secured convertible promissory notes	2,750
Proceeds from Convertible preferred stock	14,023
Purchase of Series G convertible preferred stock	$ (4,750)
Repayment of convertible promissory notes		$ (9)
Financing costs	$ (288)
Proceeds from issuance of common stock	$ 2,833	$ 1,876
Proceeds from exercise of warrants		4,975
Net cash provided by financing activities	$ 19,248	7,342
Net increase in cash and cash equivalents	64	(353)
Cash and cash equivalents, Beginning of period	214	1,033
Cash and cash equivalents, End of period	278	680
Supplemental schedule of non-cash activities:
Common stock issued as fee for debt financing arrangement	116	$ 523
Debt discount associated with convertible promissory note derivative liability	7,319
Record convertible preferred stock BCF - Series H	2,413
Series E Convertible preferred stock accretion of beneficial conversion feature as deemed dividend	490
Series E BCF conversion price reset from $7.50 to $4.50	2,835
Exchange of notes payable for Senior secured convertible debt	3,021
Note Payable to Series E preferred stock	$ 689
Convertible debentures converted and associated reclassification of derivative liabilities		$ 8,957
Debt discount written off - associated with convertible promissory notes		(1,823)
Convertible promissory note issued for payables and accrued liabilities		(2)
Stock Subscription		146
Intangible assets		(50)
Deferred funding fees charged to equity upon sale of common stock		(518)
Stock issued to acquire intangible assets		104
Reclass of Series D Preferred from mezzanine to equity		839
Stock issued to satisfy accounts payable and accrued expenses		22
Supplemental cash flow information
Interest payments	$ 17	1
Convertible promissory notes
Supplemental schedule of non-cash activities:
Common stock issued		$ 11
Series D preferred stock dividend
Supplemental schedule of non-cash activities:
Common stock issued	$ 60
Series preferred stock dividend accrued	(34)
Series E preferred stock dividend
Supplemental schedule of non-cash activities:
Common stock issued	660
Series preferred stock dividend accrued	(885)
Series G preferred stock dividend
Supplemental schedule of non-cash activities:
Common stock issued	2,088
Series preferred stock dividend accrued	$ (2,088)

General

General	9 Months Ended
	Sep. 30, 2015
General [Abstract]
GENERAL	1. GENERAL Amarantus Bioscience Holdings, Inc. (”the Company”) is a California based biopharmaceutical company founded in January 2008. We own or have exclusive licenses to various product candidates in the biopharmaceutical and diagnostic areas of the healthcare industry. We are developing our diagnostic product candidates in the field of neurology, and our therapeutic product candidates in the areas of neurology, psychiatry, ophthalmology and regenerative medicine. Our business model is to develop our product candidates through various de-risking milestones that we believe will be accretive to shareholder value, and will position them to be strategically partnered with pharmaceutical companies, diagnostic companies and/or other stakeholders in order to more efficiently achieve regulatory approval and commercialization. Amarantus Bioscience has three operating divisions: the diagnostics division; the therapeutics division; and the drug discovery division. Basis of Presentation The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements (Financial Statements) have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) and reflect all adjustments (consisting of normal recurring adjustments unless otherwise indicated) which, in the opinion of management, are necessary for a fair presentation of the results for the interim periods presented. Certain prior year amounts have been reclassified to conform to current year presentation. Certain information in footnote disclosures normally included in the financial statements prepared in conformity with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to the SEC rules and regulations for interim reporting. The financial results for the periods presented may not be indicative of the full year’s results. The Company believes the disclosures are adequate to make the information presented not misleading. These financial statements should be read in conjunction with the Company’s audited consolidated financial statements and the notes thereto for the fiscal year ended December 31, 2014 included in the Company’s Annual Report on Form 10K filed in April 2015. Significant Accounting Policies Accounting for Business Combinations Business combinations are accounted for under the acquisition method of accounting. This method requires the recording of acquired assets, including separately identifiable intangible assets, and assumed liabilities at their acquisition date fair values. The method records any excess purchase price over the fair value of acquired net assets as goodwill. The determination of the fair value of assets acquired, liabilities assumed involves assessments of factors such as the expected future cash flows associated with individual assets and liabilities and appropriate discount rates at the closing date of the acquisition. When necessary, external advisors are consulted to help determine fair value. For non-observable market values, fair values are determined using acceptable valuation principles (e.g., multiple excess earnings, relief from royalty and cost methods, discounted cash flows). Contingent consideration assumed in a business combination is remeasured at fair value each reporting period and any change in the fair value from either the passage of time or events occurring after the acquisition date, is recorded in results from operations. The results of operations are included from the acquisition date in the financial statements for all businesses acquired. Goodwill and Other Identifiable Intangibles Goodwill and indefinite-lived intangibles are reviewed annually for impairment. When testing goodwill and indefinite-lived intangibles for impairment, we first assess qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more likely than not (more than 50%) that an impairment exists. Such qualitative factors may include the following: macroeconomic conditions; industry and market considerations; cost factors; overall financial performance; and other relevant entity-specific events. In the event the qualitative assessment indicates that an impairment is more likely than not, we would be required to perform a quantitative impairment test, otherwise no further analysis is required. Under the quantitative goodwill impairment test, the evaluation of impairment involves comparing the current fair value (using Level 3 inputs) of each reporting unit to its carrying value, including goodwill. If the carrying amount of a reporting unit, including goodwill, exceeds the estimated fair value, then individual assets (including identifiable intangible assets) and liabilities of the reporting unit are estimated at fair value. The excess of the estimated fair value of the reporting unit over the estimated fair value of its net assets would establish the implied value of goodwill. The excess of the recorded amount of goodwill over the implied value is then charged to earnings as an impairment loss. In-process research & development ("IPR&D") represents the fair value assigned to research and development assets that were not fully developed at the date of acquisition. IPR&D acquired in a business combination is capitalized on the Company's consolidated balance sheet at its acquisition-date fair value. Until the project is completed, the assets are accounted for as indefinite-lived intangible assets and subject to impairment testing. Upon completion of a project, the carrying value of the related IPR&D is reclassified to intangible assets and is amortized over the estimated useful life of the asset. When performing the impairment assessment, the Company first assesses qualitative factors to determine whether it is necessary to recalculate the fair value of its acquired IPR&D. If the Company determines, as a result of the qualitative assessment, that it is more likely than not that the fair value of acquired IPR&D is less than its carrying amount, it calculates the asset's fair value. If the carrying value of the Company's acquired IPR&D exceeds its fair value, then the intangible asset is written down to its fair value. Recently Issued Accounting Pronouncements In April 2015, the Financial Accounting Standards Board issued a new pronouncement that requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability. The pronouncement becomes effective for the Company in the first quarter of 2016. Early adoption is permitted. The Company believes adoption of the pronouncement will not have a significant impact on the financial statements or its results of operations.

Liquidity and Going Concern

Liquidity and Going Concern	9 Months Ended
	Sep. 30, 2015
Liquidity And Going Concern [Abstract]
LIQUIDITY AND GOING CONCERN	2. LIQUIDITY AND GOING CONCERN The Company’s activities since inception have consisted principally of acquiring product and technology rights, raising capital, and performing research and development. Successful completion of the Company’s development programs and, ultimately, the attainment of profitable operations are dependent on future events, including, among other things, its ability to access potential markets; secure financing, develop a customer base; attract, retain and motivate qualified personnel; and develop strategic alliances. From inception, the Company has been funded by a combination of equity and debt financings. Although management believes that the Company will be able to successfully fund its operations, there can be no assurance that the Company will be able to do so or that the Company will ever operate profitably. Our activities since inception have consisted principally of acquiring product and technology rights, raising capital, and performing research and development. Historically, we have incurred net losses and negative cash flows from operations. The Company expects to continue to incur substantial losses over the next several years during its development phase. To fully execute its business plan, the Company will need to complete certain research and development activities and clinical studies. Further, the Company’s product candidates will require regulatory approval prior to commercialization. These activities may span many years and require substantial expenditures to complete and may ultimately be unsuccessful. Any delays in completing these activities could adversely impact the Company. The Company plans to meet its capital requirements primarily through issuances of debt and equity securities and, in the longer term, revenue from product sales. The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”), which contemplate continuation of the Company as a going concern. As of September 30, 2015, the Company had cash and cash equivalents of $278. Subsequent to September 30, 2015, we sold an additional 100 shares of Series E Preferred stock and received $90 of proceeds from such sales and we sold 811 shares of Series H preferred stock and received $740 of proceeds. The Company has incurred net losses and negative cash flows from operations. The Company believes its current capital resources are not sufficient to support its operations. Management intends to continue its research efforts and to finance operations of the Company through debt and/or equity financings. Management plans to seek additional debt and/or equity financing through private or public offerings or through a business combination or strategic partnership. There can be no assurance that the Company will be successful in obtaining additional financing on favorable terms, or at all. These matters raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of these uncertainties.

Business Combinations

Business Combinations	9 Months Ended
	Sep. 30, 2015
Acquisition [Abstract]
Business Combination	3. BUSINESS COMBINATIONS Acquisition of Diogenix, Inc. On January 8, 2015, we acquired DioGenix, which owns a pipeline of diagnostic tests focused on immune-mediated neurological diseases, such as multiple sclerosis (MS). Its lead product, MSPrecise, can significantly expand a physician's ability to diagnose patients that exhibit unclear neurological dysfunction. Consideration paid included 662,526 shares of Company stock valued at $12.00 per share and $900 in cash for a total consideration of $8,850. In addition, the agreement provides for a contingent payment amount up to $2,000 in cash and common stock of the Company should the acquired company achieve certain milestones related to results of clinical testing and future revenue from products in development. The fair value of the contingent consideration was estimated by applying the income approach. That measure is based on significant inputs that are not observable in the market (Level 3 inputs). Key assumptions include the discount rate of 30.4% and probability-adjusted potential outcomes. Following an acquisition, there is a period of not more than twelve months from the closing date of the acquisition to finalize the acquisition date fair values of assets acquired and liabilities assumed, including valuations of identifiable intangible assets and property and equipment. The determination of fair values of acquired intangible assets and property and equipment involves a variety of assumptions, including estimates associated with remaining useful lives. The preliminary purchase price adjustments of the assets and liabilities acquired in the January 9, 2015 Merger is $8,867. We incurred acquisition costs of $169, which were expensed. The following unaudited supplemental pro forma information presents the financial results as if the Merger had occurred on January 1, 2014. This supplemental pro forma information has been prepared for comparative purposes and does not purport to be indicative of what would have occurred had the acquisition been made on January 1, 2014, nor is it indicative of any future results. Three months ended September 30, 2014 Nine months ended September 30, 2014 Net Sales $ — $ — Operating Expenses 207 1,4400 Loss from operations $ (207 ) $ (1,440 ) Total other expenses (117 ) (351 ) Net Loss $ (324 ) $ (1,791 ) Basic and diluted net loss per common share $ (0.06 ) $ (0.38 ) Basic and diluted weighted average common shares outstanding 5,118,000 and 4,744,000, respectively. Condensed Consolidated Statement of Operations net loss for the third quarter of 2015 and year to date was $5,446 and $17,746 respectively, which included the results of DioGenix after the merger on January 9, 2015. The loss incurred during the first eight days of January 2015 is immaterial for comparison purposes.

Net Loss Per Share

Net Loss Per Share	9 Months Ended
	Sep. 30, 2015
Net Loss Per Share [Abstract]
NET LOSS PER SHARE	4. NET LOSS PER SHARE The following table sets forth the computation of the basic and diluted net loss per share attributable to the Company’s common stockholders for the periods indicated: For the Three Months Ended September 30, For the Nine Months Ended September 30, 2015 2014 2015 2014 Numerator: Net loss $ (5,446 ) $ (4,399 ) $ (17,746 ) $ (13,965 ) Preferred stock dividend 2,390 26 6,406 78 Net loss attributable to common stockholders $ (7,836 ) $ (4,425 ) $ (24,152 ) $ (14,043 ) Denominator: Common stock – basic 8,000,000 5,118,000 7, 157,000 4,744,000 Net loss per share $ (0.98 ) $ (0.86 ) $ (3.37 ) $ (2.96 ) Potentially dilutive securities: September 30, 2015 September 30, 2014 Outstanding common stock options (1) 366,000 156,000 Outstanding performance based and market based common stock options 27,000 27,000 Outstanding preferred stock option (1) 17,000 17,000 Common Stock Purchase Warrants (1) 4,699,000 311,000 Related party liability 213,000 18,000 Convertible senior secured promissory note(s) (1) 6,702,000 32,000 Convertible preferred stock Series C (1) 5,000 5,000 Convertible preferred stock Series D (1) -- 287,000 Convertible preferred stock Series E (1) 1,318,000 -- Convertible preferred stock Series H (1) 3,370,000 -- (1) The impact of stock options, warrants, convertible debt instruments and convertible preferred stock which do not have participation rights is anti-dilutive in a period of loss from continuing operations.

Intangible Assets

Intangible Assets	9 Months Ended
	Sep. 30, 2015
Intangible Assets [Abstract]
INTANGIBLE ASSETS	5. INTANGIBLE ASSETS The following table summarizes our intangible assets: Period Ended September 30, 2015 December 31, 2014 Intangibles – Acquisition Diogenix (Preliminary IPRD) $ 8,812 $ — Intangibles – Acquisition patents 4,000 — Licenses 1,685 1,685 Accumulated amortization (283 ) (188 ) Total licenses, net 1,402 1,497 Total intangible assets, net $ 14,214 $ 1,497 Intangible assets are amortized over the expected remaining lives of the respective patents. As of September 30, 2015, amortization expense for the next five years is expected to be as follows: 2015 (remaining three months) $ 64 2016 128 2017 128 2018 128 2019 128 thereafter 857 Total $ 1,433 Acquisition of Diogenix (Preliminary IPRD) On January 8, 2015, we acquired DioGenix, which owns the intellectual property rights related to a pipeline of diagnostic tests focused on immune-mediated neurological diseases, such as multiple sclerosis (MS). Its lead product, MSPrecise, can significantly expand a physician's ability to diagnose patients that exhibit unclear neurological dysfunction. Consideration paid included 662,526 shares of Company stock valued at $12.00 per share and $900 in cash for a total consideration of $8,850. In addition, the agreement provides for a contingent payment amount up to $2,000 in cash and common stock of the Company should the acquired company achieve certain milestones related to results of clinical testing and future revenue from products in development. Asset Acquired Engineered Skin Substitute Intellectual Property - Lonza Walkersville On July 8, 2015, Amarantus Bioscience Holdings, Inc. (the “Company”) exercised its previously disclosed option to acquire Intellectual property rights on the Engineered Skin Substitute for $4,000. Pursuant to the Agreement, the Company will be required to pay up to $5,000 in aggregate milestone payments upon the achievement of certain regulatory milestones, none of which have currently been met.

Notes Payable

Notes Payable	9 Months Ended
	Sep. 30, 2015
Debt Disclosure [Abstract]
NOTE PAYABLE	6. NOTES PAYABLE Notes Payable On July 1, 2015, the Company entered into a Securities Purchase Agreement (the “SPA”) with an institutional investor (the “Investor”) pursuant to which such Investor purchased an aggregate of $650 in principal amount of 12% Promissory Notes (the “Notes”) due April 2, 2016 (the “Note Transaction”). This note was shortly thereafter converted into 766 shares of Series E Convertible Preferred Stock with a 10% OID discount. On July 9, 2015, the Company entered into a Securities Purchase Agreement (the “Notes SPA”) with four investors (the “Investors”) pursuant to which such Investors purchased an aggregate of $1,000 in principal amount of 12% Promissory Notes (the “Notes”) due July 9, 2016 (the “Note Purchase Transaction”). In connection with these Note Transactions, effective on July 9, 2015, the Company entered into a Security Agreement with the Investors (the “Security Agreement”) pursuant to which the Company agreed to grant a security interest in certain of its property (the “Collateral”) to the Investors in order to secure the prompt payment, performance and discharge in full of all of the Company’s obligations under the Notes. Other Miscellaneous Notes Payable During the third quarter the Company also issued multiple other Notes Payable which aggregated $180 of principal (with weighted average interest rates of 14%). These Notes Payable are generally due within one year of issuance. In the event of default 130% of principal is owed. Events of default include failure to pay principal when due and other customary events of default, which includes cross default provisions. EVENTS OF DEFAULT The Company is currently is in compliance with all Notes Payable.

Senior Secured Convertible Prom

Senior Secured Convertible Promissory Notes	9 Months Ended
	Sep. 30, 2015
Debt Disclosure [Abstract]
SENIOR SECURED CONVERTIBLE PROMISSORY NOTES	7. SENIOR SECURED CONVERTIBLE PROMISSORY NOTES 12% Senior Secured Convertible Promissory Note and Warrants Delafield Notes On September 30, 2015, the Company entered into a Securities Purchase Agreement (the “Notes SPA”) with an institutional investor for the sale of an aggregate principal amount $3,056 (including 10% OID) 12% Senior Secured Convertible Promissory Notes due September 29, 2016 (the “Senior Secured Notes”) and a warrant to purchase 1,299,000 shares of common stock (the “PP Warrant”) in a private placement offering (the “PP Offering”). The gross proceeds to the Company from the PP Offering were $2,750. The PP Warrant is exercisable at any time on or after the earlier to occur of (i) all shares of common stock underlying the PP Warrant are registered for resale under the Securities Act of 1933, and (ii) the date six (6) months from September 30, 2015 (the earlier to occur of (i) and (ii), the “Initial Exercise Date”) and on or prior to the close of business on the five-year anniversary of the Initial Exercise Date at an exercise price of $2.00 per share. The terms of the warrants had reset provisions that precluded their inclusion as equity and was recorded as a derivative liability. See footnote 8. Dominion Notes On September 30, 2015, the Company entered into an exchange agreement (the “Exchange Agreement”) with an existing institutional investor pursuant to which the existing investor exchanged $3,021 (including OID and make-whole) aggregate principal amount of Notes Payable, which included principal and accrued interest for Senior Secured Convertible Notes of the Company for $3,021 aggregate principal amount of Senior Secured Notes and a common stock purchase warrant to purchase 1,299,000 with a $2.00 exercise price. Interest Terms The principal amount of the Senior Secured Notes shall accrue interest at a rate equal to 12% per annum, payable on the Maturity Date in cash, or, at the Company’s option, in common stock or a combination thereof. At any time upon five (5) days written notice to the Investor, the Company may prepay any portion of the principal amount of the Senior Secured Notes and any accrued and unpaid interest at an amount equal to 120% of the then outstanding principal amount of the Senior Secured Notes and accrued interest or 130% if a Qualified Financing (as defined in the Senior Secured Notes) has occurred. Security interest In connection with the issuance of the Senior Secured Convertible Promissory Notes, the Company granted a security interest in all of its assets to the note holders. Events of Default The Senior Secured Notes contain certain customary Events of Default (including, but not limited to, default in payment of principal or interest thereunder, breaches of covenants, agreements, representations or warranties thereunder, the occurrence of an event of default under certain material contracts of the Company, including the transaction documents relating to the PP Offering, changes in control of the Company, filing of bankruptcy and the entering or filing of certain monetary judgments against the Company). Upon the occurrence of any such Event of Default the outstanding principal amount of the Senior Secured Notes, plus accrued but unpaid interest, liquidated damages, and other amounts owing in respect thereof through the date of acceleration, shall become, at the Investor’s election, immediately due and payable in cash. Upon any Event of Default that results in acceleration of the Senior Secured Notes, the interest rate on the Senior Secured Notes shall accrue at an interest rate equal to the lesser of 24% per annum or the maximum rate permitted under applicable law. The Company is currently is in compliance with all Senior Secured Convertible Promissory Notes. Conversion Features At any time after the issuance date of the Senior Secured Notes until all amounts due have been paid in full, the Senior Secured Note shall be convertible, in whole or in part, into shares of common stock at the option of the holder, at any time and from time to time. The conversion price in effect on any conversion date shall be equal to the lowest of (i) $2.50, (ii) 75% of the lowest daily VWAP in the fifteen (15) trading days prior to the conversion date, or (iii) (A) if a Public Offering (as defined in the Senior Secured Note) that is not a Qualified Public Offering (as defined in the Senior Secured Note) has occurred, 75% or (B) if a Qualified Public Offering has occurred, 80% of the lowest of the (x) per share price of shares of common stock, and (y) the lowest conversion price, exercise price or exchange price of any common stock equivalents, that are sold or issued to the public in the Public Offering or the Qualified Public Offering, respectively. The conversion features of the notes were bifurcated from the host instrument as its conversion terms were not indexed to the company’s own stock. In addition, the warrants associated with the debt instruments were also treated as a free standing derivative liability. The total fair value of the embedded conversion feature and the warrants exceeded the net proceeds received and resulted in a loss in issuance of $1,045. See footnote 8 for inputs utilized in fair valuing the conversion option and notes.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2015
Fair Value Measurements [Abstract]
FAIR VALUE MEASUREMENTS	8. FAIR VALUE MEASUREMENTS Accounting standards have been issued which define fair value, establishes a market-based framework or hierarchy for measuring fair value and expands disclosures about fair value measurements. The standard is applicable whenever another accounting pronouncement requires or permits assets and liabilities to be measured at fair value. The standard does not expand or require any new fair value measures; however its application may change current practice. Fair value is defined under the standard as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date. The standard also establishes a three-level hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value: ● Level 1 ● Level 2 ● Level 3 The Company’s financial assets and liabilities that are measured at fair value on a recurring basis as of September 30, 2015 by level within the fair value hierarchy, are as follows: Fair Value Measurements at September 30, 2015 Level 1 Level 2 Level 3 Total Warrant liability $ — $ — $ 3,720 $ 3,720 Derivative Liability — — 4,645 4,645 Total fair value $ — $ — $ 8,365 $ 8,365 The following table provides a summary of changes in the fair value of the Company’s Level 3 financial liabilities for September 2015: Warrant Liability Derivative Liability Total December 31, 2014 $ — $ — $ — Issuance of convertible notes — 3,720 3,720 Issuance of warrants 4,645 — 4,645 September 30, 2015 $ 4,645 $ 3,720 $ 8,365 As of September 30, 2015, the fair value of the warrant liability is $4,645 and the derivative liability is $3,720 and $232,988, The fair value of the warrants at September 30, 2015 were determined using the Black-Scholes model with the following assumptions: Warrant Derivative Contractual life (years) 5 1 Annualized volatility 250 % 97 % Conversion price $ 2.00 $ 0.91 Expected dividends 0 % 0 % Risk-free investment rate 1.3 % 0.3 %

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2015
Commitments and Contingencies [Abstract]
COMMITMENTS AND CONTINGENCIES	9. COMMITMENTS AND CONTINGENCIES Commitments: Sponsored Research Arrangements: We entered into a number of sponsored research agreements during 2014, primarily, which require us to make future payments as follows: 2015 (remaining) $ 102 2016 150 Total $ 252 Research, License, and Option to License Arrangements The Company is a party to various agreements that obligate it to make certain payments:

Equity

Equity	9 Months Ended
	Sep. 30, 2015
Equity [Abstract]
EQUITY	10. EQUITY Series G Preferred Stock Issuance In the second quarter the Company issued 1,087 shares of Series G Preferred stock for gross proceeds of $5,000, which was net of 8% original issue discount. On July 10, 2015, the Company entered into an Amended and Restated Securities Purchase Agreement (the “Series G SPA”) with an institutional investor for the sale of 435 shares of the Company’s Series G Preferred Stock and an additional 100 shares of Series G Preferred Stock as a fee (collectively, the “Shares”) in a registered direct offering (the “Offering”), subject to customary closing conditions. The gross proceeds to the Company from the registered direct offering were $2,000. Closing conditions were met on July 10, 2015 and the transaction was closed on July 13, 2015. The Series G Preferred Stock has a fixed conversion price of $9.00. Repurchase Agreement On September 25, 2015, the Company entered into a repurchase agreement (the “Repurchase Agreement”) with the holder of all of the Company’s issued and outstanding Series G Preferred Stock (the “Series G Holder”) pursuant to which the Company has repurchased the remaining 1,280 are of Series G Preferred Stock and all shares of common stock held by the Series G Holder for an aggregate purchase price of $4,750. As of October 1, 2015, there are no more shares of Series G Preferred Stock issued and outstanding. Conversions during the Quarter 342 shares of Series G converted through September 30, 2015 into 190,000 of common shares. In addition, the holders upon conversion received a conversion premium amount based on an agreed upon dividend rate which ranged 13-24% and six years from the date of notice of exercise. In aggregate a conversion premium amount of $1,949 was due the holders. The conversion premium amount was converted into common stock based upon an agreed upon discount to the common stock price, which ranged between $0.90 to $3.40. This resulted in additional common stock issued of approximately 1,416,000. Series H Preferred Stock and Warrants On September 30, 2015, Amarantus BioScience Holdings, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Series H SPA”) with an institutional investor for the sale of 3,055.556 (including 10% OID) shares of the Company’s 12% Series H Preferred Stock (the “Series H Preferred Stock”) and a warrant to purchase 1,299,000 shares of common stock (the “RD Warrant” and together with the Series H Preferred Stock, the “Securities”) in a registered direct offering (the “RD Offering”), subject to customary closing conditions. The gross proceeds to the Company from the RD Offering were $2,413, net of $337 of legal fees. Each share of Series H Preferred Stock has a stated value of $1,000 and is convertible into shares of common stock at an initial conversion price of the lower of (i) $2.50, subject to adjustment and (ii) 75%, subject to adjustment, of the lowest volume weighted average price, or VWAP, during the fifteen (15) Trading Days immediately prior to the date a conversion notice is sent to the Company by a holder, at any time at the option of the holder. The proceeds of the raise was used to buyout the holders of the Series G. A minimal amount was remaining and was included as a dividend. The RD Warrant is exercisable at any time on or after the earlier to occur of (i) all shares of common stock underlying the RD Warrant are registered for resale under the Securities Act of 1933, and (ii) the date six (6) months from September 30, 2015 (the earlier to occur of (i) and (ii), the “Initial Exercise Date”) and on or prior to the close of business on the five-year anniversary of the Initial Exercise Date at an exercise price of $2.00 per share. The warrant had price protection terms that precluded an equity classification, as such $1,548 was recorded as a derivative liability and recorded as net of proceeds. The allocation of proceeds associated with the warrants resulted in an effective conversion price that was in the money by $0.94, a beneficial conversion feature. The beneficial conversion feature was limited to $865 and along with the warrant was accreted back as a deemed dividend of $2,413. Nervada Warrants The Company 500,000 common stock purchase warrants to acquire to lock-up common shares held. The warrants are exercisable at $0.01 per unit. The Company fair valued the warrant at $600,000 and recorded a loss on issuance. The inputs included exercise price of $0.01, contractual term of 5 years, volatility of 250% and risk free rate of 1%. The warrants are exercisable on September 30, 2016.

Stock Option Plans

Stock Option Plans	9 Months Ended
	Sep. 30, 2015
Stock Option Plans [Abstract]
STOCK OPTION PLANS	11. STOCK OPTION PLANS Stock-based compensation expense for all plans is classified in the statements of operations as follows: Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Research and development $ 93 $ 123 $ 254 $ 311 General and administrative 308 315 955 603 Total $ 401 $ 438 $ 1,209 $ 914 At September 30, 2015, there was a total of approximately $2,732 of unrecognized compensation cost, related to non-vested stock option awards, which is expected to be recognized over a weighted-average period of approximately 2.7 years.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2015
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	12. SUBSEQUENT EVENTS Series H Preferred Stock and Warrants Subsequent to September 30, 2015, we sold 822 shares of Series H Preferred Stock and warrants for gross proceeds of $750. All terms and conditions of this Series H Preferred Stock and warrants were the same as those described in Note 10. 2,300,000 common shares were issued in connection with the conversion of 891 Series H Preferred stock subsequent to September 30, 2015. 1,578,000 shares of common stock were issued associated with the conversion of $550 of senior secured convertible promissory notes. Approximately 508,000 common shares were issued to satisfy accrued dividends associated with preferred stock and common stock services.

General (Policies)

General (Policies)	9 Months Ended
	Sep. 30, 2015
General [Abstract]
Accounting for Business Combinations	Accounting for Business Combinations Business combinations are accounted for under the acquisition method of accounting. This method requires the recording of acquired assets, including separately identifiable intangible assets, and assumed liabilities at their acquisition date fair values. The method records any excess purchase price over the fair value of acquired net assets as goodwill. The determination of the fair value of assets acquired, liabilities assumed involves assessments of factors such as the expected future cash flows associated with individual assets and liabilities and appropriate discount rates at the closing date of the acquisition. When necessary, external advisors are consulted to help determine fair value. For non-observable market values, fair values are determined using acceptable valuation principles (e.g., multiple excess earnings, relief from royalty and cost methods, discounted cash flows). Contingent consideration assumed in a business combination is remeasured at fair value each reporting period and any change in the fair value from either the passage of time or events occurring after the acquisition date, is recorded in results from operations. The results of operations are included from the acquisition date in the financial statements for all businesses acquired.
Goodwill and Other Identifiable Intangibles	Goodwill and Other Identifiable Intangibles Goodwill and indefinite-lived intangibles are reviewed annually for impairment. When testing goodwill and indefinite-lived intangibles for impairment, we first assess qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more likely than not (more than 50%) that an impairment exists. Such qualitative factors may include the following: macroeconomic conditions; industry and market considerations; cost factors; overall financial performance; and other relevant entity-specific events. In the event the qualitative assessment indicates that an impairment is more likely than not, we would be required to perform a quantitative impairment test, otherwise no further analysis is required. Under the quantitative goodwill impairment test, the evaluation of impairment involves comparing the current fair value (using Level 3 inputs) of each reporting unit to its carrying value, including goodwill. If the carrying amount of a reporting unit, including goodwill, exceeds the estimated fair value, then individual assets (including identifiable intangible assets) and liabilities of the reporting unit are estimated at fair value. The excess of the estimated fair value of the reporting unit over the estimated fair value of its net assets would establish the implied value of goodwill. The excess of the recorded amount of goodwill over the implied value is then charged to earnings as an impairment loss. In-process research & development ("IPR&D") represents the fair value assigned to research and development assets that were not fully developed at the date of acquisition. IPR&D acquired in a business combination is capitalized on the Company's consolidated balance sheet at its acquisition-date fair value. Until the project is completed, the assets are accounted for as indefinite-lived intangible assets and subject to impairment testing. Upon completion of a project, the carrying value of the related IPR&D is reclassified to intangible assets and is amortized over the estimated useful life of the asset. When performing the impairment assessment, the Company first assesses qualitative factors to determine whether it is necessary to recalculate the fair value of its acquired IPR&D. If the Company determines, as a result of the qualitative assessment, that it is more likely than not that the fair value of acquired IPR&D is less than its carrying amount, it calculates the asset's fair value. If the carrying value of the Company's acquired IPR&D exceeds its fair value, then the intangible asset is written down to its fair value.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In April 2015, the Financial Accounting Standards Board issued a new pronouncement that requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability. The pronouncement becomes effective for the Company in the first quarter of 2016. Early adoption is permitted. The Company believes adoption of the pronouncement will not have a significant impact on the financial statements or its results of operations.

Business Combinations (Tables)

Business Combinations (Tables)	9 Months Ended
	Sep. 30, 2015
Acquisition [Abstract]
Schedule of supplemental pro forma information	Three months ended September 30, 2014 Nine months ended September 30, 2014 Net Sales $ — $ — Operating Expenses 207 1,4400 Loss from operations $ (207 ) $ (1,440 ) Total other expenses (117 ) (351 ) Net Loss $ (324 ) $ (1,791 ) Basic and diluted net loss per common share $ (0.06 ) $ (0.38 )

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2015
Net Loss Per Share [Abstract]
Schedule of computation of the basic and diluted net loss per share	For the Three Months Ended September 30, For the Nine Months Ended September 30, 2015 2014 2015 2014 Numerator: Net loss $ (5,446 ) $ (4,399 ) $ (17,746 ) $ (13,965 ) Preferred stock dividend 2,390 26 6,406 78 Net loss attributable to common stockholders $ (7,836 ) $ (4,425 ) $ (24,152 ) $ (14,043 ) Denominator: Common stock – basic 8,000,000 5,118,000 7, 157,000 4,744,000 Net loss per share $ (0.98 ) $ (0.86 ) $ (3.37 ) $ (2.96 ) Potentially dilutive securities: September 30, 2015 September 30, 2014 Outstanding common stock options (1) 366,000 156,000 Outstanding performance based and market based common stock options 27,000 27,000 Outstanding preferred stock option (1) 17,000 17,000 Common Stock Purchase Warrants (1) 4,699,000 311,000 Related party liability 213,000 18,000 Convertible senior secured promissory note(s) (1) 6,702,000 32,000 Convertible preferred stock Series C (1) 5,000 5,000 Convertible preferred stock Series D (1) -- 287,000 Convertible preferred stock Series E (1) 1,318,000 -- Convertible preferred stock Series H (1) 3,370,000 --

Intangible Assets (Tables)

Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2015
Intangible Assets [Abstract]
Summarizes of intangible assets	Period Ended September 30, 2015 December 31, 2014 Intangibles – Acquisition Diogenix (Preliminary IPRD) $ 8,812 $ — Intangibles – Acquisition patents 4,000 — Licenses 1,685 1,685 Accumulated amortization (283 ) (188 ) Total licenses, net 1,402 1,497 Total intangible assets, net $ 14,214 $ 1,497
Summarizes intangible assets amortization expense	2015 (remaining three months) $ 64 2016 128 2017 128 2018 128 2019 128 thereafter 857 Total $ 1,433

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2015
Fair Value Measurements [Abstract]
Schedule of financial assets and liabilities that are measured at fair value on a recurring basis	Level 1 Level 2 Level 3 Total Warrant liability $ — $ — $ 3,720 $ 3,720 Derivative Liability — — 4,645 4,645 Total fair value $ — $ — $ 8,365 $ 8,365
Summary of changes in the fair value of the company's Level 3 financial liabilities	Warrant Liability Derivative Liability Total December 31, 2014 $ — $ — $ — Issuance of convertible notes — 3,720 3,720 Issuance of warrants 4,645 — 4,645 September 30, 2015 $ 4,645 $ 3,720 $ 8,365
Schedule of fair value of the warrants determined using the Black-Scholes model with the following assumptions	Warrant Derivative Contractual life (years) 5 1 Annualized volatility 250 % 97 % Conversion price $ 2.00 $ 0.91 Expected dividends 0 % 0 % Risk-free investment rate 1.3 % 0.3 %

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2015
Commitments and Contingencies [Abstract]
Schedule of sponsored research arrangements future payments	2015 (remaining) $ 102 2016 150 Total $ 252

Stock Option Plans (Tables)

Stock Option Plans (Tables)	9 Months Ended
	Sep. 30, 2015
Stock Option Plans [Abstract]
Summary of Stock-based compensation expense classified in statements of operations	Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Research and development $ 93 $ 123 $ 254 $ 311 General and administrative 308 315 955 603 Total $ 401 $ 438 $ 1,209 $ 914

Liquidity and Going Concern (De

Liquidity and Going Concern (Details Textual) - USD ($)	3 Months Ended			9 Months Ended
	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Sep. 30, 2015	Dec. 31, 2014	Sep. 30, 2014	Dec. 31, 2013
Liquidity and Going Concern (Textual)
Cash and cash equivalents	$ 278,000			$ 278,000	$ 214,000	$ 680,000	$ 1,033,000
Proceeds from sale of stock			$ 2,820,000
Series G Preferred Stock [Member]
Liquidity and Going Concern (Textual)
Stock issued during period shares		1,087
Proceeds from sale of stock		$ 5,000,000
Series G Preferred Stock [Member] | Stock Purchase Agreement [Member] | Cayman Islands [Member]
Liquidity and Going Concern (Textual)
Stock issued during period shares				811
Proceeds from sale of stock				$ 2,000,000
Percentage of original issue discount				8.00%
Series E Preferred Stock [Member]
Liquidity and Going Concern (Textual)
Stock issued during period shares		444	3,278
Proceeds from sale of stock		$ 400,000	$ 2,950,000
Series E Preferred Stock [Member] | Subsequent Event [Member]
Liquidity and Going Concern (Textual)
Stock issued during period shares				100
Proceeds from sale of stock				$ 90,000
Series H Preferred Stock [Member]
Liquidity and Going Concern (Textual)
Proceeds from sale of stock				$ 740
Series H Preferred Stock [Member] | Subsequent Event [Member]
Liquidity and Going Concern (Textual)
Stock issued during period shares				822

Business Combinations (Details)

Business Combinations (Details) - DioGenix, Inc [Member] - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2014
Business Acquisition [Line Items]
Net Sales
Operating Expenses	$ 207	$ 14,400
Loss from operations	(207)	(1,440)
Total other expenses	(117)	(351)
Net Loss	$ (324)	$ (1,791)
Basic and diluted net loss per common share	$ (0.06)	$ (0.38)

Business Combinations (Details

Business Combinations (Details Textual) - USD ($)	Jan. 08, 2015	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Acquisition (Textual)
Acquisition costs				$ 169,000
Purchase price of adjustments of the assets and liabilities		$ 8,867,000		8,867,000
Gross proceeds from sale of shares				$ 2,750
Weighted Average Number of Shares Outstanding, Basic and Diluted		8,000,000	5,118,000	7,157,031	4,744,000
DioGenix, Inc [Member]
Acquisition (Textual)
Contingent payment in cash				$ 2,000,000
Discount rate				30.40%
Net loss		$ 5,446,000		$ 17,746,000
Consideration paid in shares	662,526
Stock price per share	$ 12
Cash consideration	$ 900

Net Loss Per Share (Details)

Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended				9 Months Ended
		Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Numerator:
Net loss		$ (5,722)	$ (5,721)	$ (6,580)	$ (4,399)	$ (12,302)	$ (13,965)
Preferred stock dividend		3,187			26	4,016	78
Net loss attributable to common stockholders		$ (8,909)			$ (4,425)	$ (16,318)	$ (14,043)
Denominator:
Common stock - basic		8,000,000			5,118,000	7,157,000	4,744,000
Common shares equivalents	[1]	1,192,554				932,437
Weighted avg. shares outstanding:		80,000,000			5,118,000	7,157,000	4,744,000
Net loss per share		$ (0.98)			$ (0.86)	$ (3.37)	$ (2.96)
Potentially dilutive securities:
Outstanding common stock options	[2]					366,000	23,344,000
Outstanding performance based and market based common stock options						26,667	4,000,000
Outstanding preferred stock option	[2]					17,000	2,488,000
Common Stock Purchase Warrants	[2]					4,699,000	46,637,000
Related party liability	[2]					213,000	2,743,000
Convertible senior secured promissory note	[2]					6,702,022	4,725,000
Series C Preferred Stock [Member]
Potentially dilutive securities:
Convertible preferred stock	[2]					5,000	750,000
Series D Preferred Stock [Member]
Potentially dilutive securities:
Convertible preferred stock	[2]						43,111,000
Series E Preferred Stock [Member]
Potentially dilutive securities:
Convertible preferred stock	[2]					9,888
Series H Preferred Stock [Member]
Potentially dilutive securities:
Convertible preferred stock	[2]					3,056
[1]	Preferred Stock Series D, E and G are participating securities; therefore we utilize the two class method of computing net loss per share.
[2]	The impact of stock options, warrants, convertible debt instruments and convertible preferred stock which do not have participation rights is anti-dilutive in a period of loss from continuing operations.

Intangible Assets (Details)

Intangible Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Intangible assets consist of:
Accumulated amortization	$ (283)	$ (188)
Total licenses, net	1,402	1,497
Total intangible assets, net	14,214	1,497
License [Member]
Intangible assets consist of:
Licenses	1,685	$ 1,685
Acquisition Diogenix (Preliminary IPRD) [Member]
Intangible assets consist of:
Total licenses, net	8,812
Acquisition patents [Member]
Intangible assets consist of:
Total licenses, net	$ 4,000

Intangible Assets (Details 1)

Intangible Assets (Details 1) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Finite-Lived Intangible Assets [Line Items]
2015 (remaining three months)	$ 64
2,016	128
2,017	128
2,018	128
2,019	128
thereafter	857
Total	$ 14,213	$ 1,497

Intangible Assets (Details Text

Intangible Assets (Details Textual) - USD ($)	Jan. 08, 2015	Sep. 30, 2015
Intangible assets (Textual)
Gross proceeds from sale of shares		$ 2,750
DioGenix, Inc [Member]
Intangible assets (Textual)
Consideration paid in shares	662,526
Stock price per share	$ 12
Cash consideration	$ 900

Notes Payable (Details)

Notes Payable (Details) - USD ($) $ in Thousands	1 Months Ended		9 Months Ended
	Jul. 31, 2015	Jul. 10, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015
Short-term Debt [Line Items]
Debt instrument, face amount		$ 1,000	$ 2,850
Interest rate		12.00%	12.00%
Maturity Date		Jul. 9, 2016	Sep. 29, 2016
Conversion of preferred stock			1,949
Miscellaneous Notes Payable [Member]
Short-term Debt [Line Items]
Debt instrument, face amount			$ 180
Interest rate			14.00%
Other miscellaneous notes payable description			In the event of default 130% of principal is owed.
Series E Convertible Preferred Stock [Member]
Short-term Debt [Line Items]
Debt instrument, face amount	$ 650
Interest rate	12.00%		12.00%	12.00%	12.00%
Maturity Date	Apr. 2, 2016
Conversion of preferred stock	766
Discount percentage on preferred stock	10.00%

Senior Secured Convertible Pr35

Senior Secured Convertible Promissory Notes (Details)	1 Months Ended	3 Months Ended		9 Months Ended
	Jul. 10, 2015	Sep. 30, 2015USD ($)$ / shares	Jun. 30, 2015USD ($)	Sep. 30, 2015USD ($)$ / sharesshares
Debt Instrument [Line Items]
Aggregate principal amount
Interest rate	12.00%	12.00%		12.00%
Maturity Date	Jul. 9, 2016			Sep. 29, 2016
Exercise price | $ / shares		$ 2		$ 2
percentage of OID				8
12% Senior Secured Convertible Promissory Note and Warrants [Member]
Debt Instrument [Line Items]
Description of debt instrument				The principal amount of the Senior Secured Notes shall accrue interest at a rate equal to 12% per annum, payable on the Maturity Date in cash, or, at the Company's option, in common stock or a combination thereof. At any time upon five (5) days written notice to the Investor, the Company may prepay any portion of the principal amount of the Senior Secured Notes and any accrued and unpaid interest at an amount equal to 120% of the then outstanding principal amount of the Senior Secured Notes and accrued interest or 130% if a Qualified Financing (as defined in the Senior Secured Notes) has occurred.
Embedded conversion feature				$ 1,045
12% Senior Secured Convertible Promissory Note and Warrants [Member] | Secured Debt [Member]
Debt Instrument [Line Items]
Description of debt instrument				The conversion price in effect on any conversion date shall be equal to the lowest of (i) $2.50, (ii) 75% of the lowest daily VWAP in the fifteen (15) trading days prior to the conversion date, or (iii) (A) if a Public Offering (as defined in the Senior Secured Note) that is not a Qualified Public Offering (as defined in the Senior Secured Note) has occurred, 75% or (B) if a Qualified Public Offering has occurred, 80% of the lowest of the (x) per share price of shares of common stock, and (y) the lowest conversion price, exercise price or exchange price of any common stock equivalents, that are sold or issued to the public in the Public Offering or the Qualified Public Offering, respectively.
12% Senior Secured Convertible Promissory Note and Warrants [Member] | Securities Purchase Agreement [Member]
Debt Instrument [Line Items]
Aggregate principal amount				$ 3,056
Interest rate		12.00%		12.00%
Maturity Date				Sep. 29, 2016
Warrant to purchase | shares				1,299,000
Gross proceeds				$ 2,750
Exercise price | $ / shares		$ 2		$ 2
Description of debt instrument				(i) all shares of common stock underlying the PP Warrant are registered for resale under the Securities Act of 1933, and (ii) the date six (6) months from September 30, 2015 (the earlier to occur of (i) and (ii), the "Initial Exercise Date") and on or prior to the close of business on the five-year anniversary of the Initial Exercise Date at an exercise price of $2.00 per share.
percentage of OID				0.10
12% Senior Secured Convertible Promissory Note and Warrants [Member] | Exchange Agreement [Member]
Debt Instrument [Line Items]
Aggregate principal amount				$ 3,021
Warrant to purchase | shares				1,299,000
Exercise price | $ / shares		$ 2		$ 2

Fair Value Measurements (Detail

Fair Value Measurements (Details) $ in Thousands	Sep. 30, 2015USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant Liability	$ 4,645
Derivative Liability	3,720
Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant Liability	3,720
Derivative Liability	4,645
Total fair value	$ 8,365
Fair Value Measurements Level 1 [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant Liability
Derivative Liability
Total fair value
Fair Value Measurements Level 2 [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant Liability
Derivative Liability
Total fair value
Fair Value Measurements Level 3 [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant Liability	$ 3,720
Derivative Liability	4,645
Total fair value	$ 8,365

Fair Value Measurements (Deta37

Fair Value Measurements (Details 1) - Fair Value, Inputs, Level 3 [Member] $ in Thousands	9 Months Ended
	Sep. 30, 2015USD ($)
Summary of changes in the fair value of the Level 3 financial liabilities
December 31, 2014
Issuance of convertible notes	$ 3,720
Issuance of warrants	4,645
September 30, 2015	$ 8,365
Derivative Liability [Member]
Summary of changes in the fair value of the Level 3 financial liabilities
December 31, 2014
Issuance of convertible notes	$ 3,720
Issuance of warrants
September 30, 2015	$ 3,720
Warrant Liability [Member]
Summary of changes in the fair value of the Level 3 financial liabilities
December 31, 2014
Issuance of convertible notes
Issuance of warrants	$ 4,645
September 30, 2015	$ 4,645

Fair Value Measurements (Deta38

Fair Value Measurements (Details 2)	9 Months Ended
	Sep. 30, 2015$ / shares
Warrant [Member]
Summary of fair value of the warrants
Contractual life (years)	5 years
Annualized volatility	250.00%
Conversion price	$ 2
Expected dividends	0.00%
Risk-free investment rate	1.30%
Derivative [Member]
Summary of fair value of the warrants
Contractual life (years)	1 year
Annualized volatility	97.00%
Conversion price	$ 0.91
Expected dividends	0.00%
Risk-free investment rate	0.30%

Fair Value Measurements (Deta39

Fair Value Measurements (Details Textual) $ in Thousands	Sep. 30, 2015USD ($)
Fair Value Measurements [Abstract]
Warrant Liability	$ 4,645
Derivative Liability	$ 3,720

Commitments and Contingencies40

Commitments and Contingencies (Details) $ in Thousands	Sep. 30, 2015USD ($)
Commitments and Contingencies [Abstract]
2015 (remaining)	$ 102
2,016	150
Total	$ 252

Equity (Details)

Equity (Details)	1 Months Ended				3 Months Ended			9 Months Ended
	Jul. 31, 2015shares	Jul. 10, 2015$ / sharesshares	Apr. 23, 2015shares	Apr. 02, 2015shares	Sep. 30, 2015USD ($)$ / sharesshares	Jun. 30, 2015USD ($)shares	Mar. 31, 2015USD ($)shares	Sep. 30, 2015USD ($)$ / sharesshares
Equity (Textual)
Conversion of stock, shares converted								1,000
Restricted stock issued								8,333
Sale of stock description								Sale of 3,055.556 (including 10% OID) shares of the Company's 12% Series H Preferred Stock (the "Series H Preferred Stock") and a warrant to purchase 1,299,000 shares of common stock (the "RD Warrant" and together with the Series H Preferred Stock, the "Securities") in a registered direct offering (the "RD Offering"), subject to customary closing conditions. The gross proceeds to the Company from the RD Offering were $2,750. Each share of Series H Preferred Stock has a stated value of $1,000 and is convertible into shares of common stock at an initial conversion price of the lower of (i) $2.50, subject to adjustment and (ii) 75%, subject to adjustment, of the lowest volume weighted average price, or VWAP, during the fifteen (15) Trading Days immediately prior to the date a conversion notice is sent to the Company by a holder, at any time at the option of the holder.
Warrant to purchase of common stock								1,299,000
Gross proceeds from sale of shares | $								$ 2,750
Sale of stock for investor								3,055.556
Warrants exercise price description								(i) all shares of common stock underlying the RD Warrant are registered for resale under the Securities Act of 1933, and (ii) the date six (6) months from September 30, 2015 (the earlier to occur of (i) and (ii), the "Initial Exercise Date") and on or prior to the close of business on the five-year anniversary of the Initial Exercise Date at an exercise price of $2.00 per share
Exercise price | $ / shares					$ 2			$ 2
Conversion of stock amount | $								$ 190,000,000
Conversion of stock, shares issued								1,949
Conversion of Stock, Description								In addition, the holders upon conversion received a conversion premium amount based on an agreed upon dividend rate which ranged 13 -24% and six years from the date of notice of exercise.
Additional common stock share issued								1,416,000
Preferred stock original issue discount rate								8
Proceeds from sale of stock | $							$ 2,820,000
Minimum [Member]
Equity (Textual)
Common stock convertible conversion price | $ / shares								$ 0.90
Maximum [Member]
Equity (Textual)
Common stock convertible conversion price | $ / shares								$ 3.40
Common Stock [Member]
Equity (Textual)
Proceeds from sale of stock | $
Stock issued during period shares							259,595
Warrant [Member]
Equity (Textual)
Warrant to purchase of common stock								500,000
Exercise price | $ / shares					$ 0.01			$ 0.01
Volatility rate								250.00%
Risk free interest rate								1.00%
Expected term								5 years
Fair value of warrants | $								$ 600,000
Series E Preferred Stock [Member]
Equity (Textual)
Conversion of stock, shares converted							500
Convertible preferred stock, shares issued					1,400			1,400
Restricted stock issued				200,000
Conversion of stock, shares issued	766
Proceeds from sale of stock | $						$ 400,000	$ 2,950,000
Stock issued during period shares						444	3,278
Series E Preferred Stock [Member] | Common Stock [Member]
Equity (Textual)
Common stock issued dividend							5,904
Common stock issued as a dividend due upon conversion							15,835
Series G Preferred Stock [Member]
Equity (Textual)
Conversion of stock, shares converted	150
Preferred stock shares conversion price | $ / shares		$ 9
Shares issued under securities purchase agreement		435	1,087
Additional preferred stock issued as a fee		100
Repurchase of common stock | $								$ 4,750
Remaining number of common stock repurchase								1,280
Proceeds from sale of stock | $						$ 5,000,000
Stock issued during period shares						1,087

Stock Option Plans (Details)

Stock Option Plans (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 401	$ 438	$ 1,209	$ 914
Research and Development Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	93	123	254	311
General and Administrative Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 308	$ 315	$ 955	$ 603

Stock Option Plans (Details Tex

Stock Option Plans (Details Textual) $ in Thousands	9 Months Ended
	Sep. 30, 2015USD ($)
Stock Option Plans [Abstract]
Unrecognized compensation cost	$ 2,732
Expected weighted-average period	2 years 8 months 12 days

Subsequent Events (Details)

Subsequent Events (Details) - USD ($)	3 Months Ended	9 Months Ended
	Mar. 31, 2015	Sep. 30, 2015	Dec. 31, 2014
Subsequent Event [Line Items]
Proceeds from sale of shares, value		$ 2,750
Conversion of common stock		1,000
Common stock, shares issued		113,000	5,615,000
Series E Preferred Stock [Member]
Subsequent Event [Line Items]
Common shares issued in connection with conversion of stock		1,400
Conversion of common stock	500
Subsequent Event [Member] | Marc Check [Member]
Subsequent Event [Line Items]
Common stock, shares issued		2,086,000
Subsequent Event [Member] | Common Stock [Member]
Subsequent Event [Line Items]
Common shares issued in connection with conversion of stock		2,300,000
Subsequent Event [Member] | Series H Preferred Stock [Member]
Subsequent Event [Line Items]
Sale of shares		822
Conversion of common stock		891
Subsequent Event [Member] | Series E Preferred Stock [Member]
Subsequent Event [Line Items]
Sale of shares		100